Breaking
Friday, June 12, 2026

Rare Diseases

🇺🇸 FDA

FDA news and analysis for pharmaceutical BD, investment, and market access

Gain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.

Showing 1–12 of 81 articles

Quick answer

NovaPharmaNews Rare Diseases hub for FDA covers 81 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.

Critical impact AnalysisJun 7, 2026

Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis

FDA · rare disease · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

FDA Priority Review Voucher Program: Will Makary's Initiative Survive?

FDA · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 4, 2026

BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams

FDA · rare disease · 6 min

Dr. Sarah Mitchell
High impact AnalysisJun 3, 2026

FDA Hold Puts Aardvark Prader-Willi Drug in Limbo: Implications for Pharma BD

FDA · Prader-Willi syndrome · 8 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal

muscular dystrophy · 13 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Immunovant's IMVT-1402 Shows Blockbuster Potential in Autoimmune Disease; Wave Life Sciences Advances RNA Editing

FDA · autoimmune disease · 9 min

Dr. Sarah Mitchell
High impact NewsJun 2, 2026

Global Regulatory Roundup: Key Updates for June 1, 2026

FDA · Dermatologicals · 7 min

Dr. Sarah Mitchell
Medium impact AnalysisMay 23, 2026

Palvella Secures $230M to Advance QTORIN for Rare Diseases

rare disease · 2 min

Dr. Sarah Mitchell
Medium impact AnalysisMay 21, 2026

Palvella's Pivotal Rare-Disease Data and Financial Outlook

rare disease · 4 min

Dr. Sarah Mitchell
Medium impact AnalysisMay 20, 2026

Palvella's Nasdaq Uplisting: Implications for Rare Disease Development

rare disease · 3 min

Dr. Sarah Mitchell
Medium impact AnalysisMay 18, 2026

Palvella's Pivotal Data and Cash Runway: Implications for Rare Diseases

rare disease · 5 min

Dr. Sarah Mitchell
Critical impact NewsMay 15, 2026

Fierce Biotech Week: Key Takeaways and Emerging Trends

biotech · 12 min

Dr. Laura Bennett

Frequently asked questions

How often is this topic updated?

New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.

Where does this coverage come from?

Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.